Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1146/annurev-pathol-012414-040349 http://scihub22266oqcxt.onion/10.1146/annurev-pathol-012414-040349 C6028239!6028239!27022975     free     free     free Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\27022975.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Annu+Rev+Pathol 2016 ; 11 (ä): 617-44 Nephropedia Template TP {{tp|p=27022975|t=2016. The Roles of MDM2 and MDMX in Cancer |pdf=|usr=}}{{27022975}} gab.com Text The Roles of MDM2 and MDMX in Cancer JO: Annu Rev Pathol http://www.kidney.de/pget.php?&tw=1&pmid=27022975 #FOAvip For more than 25 years, MDM2 and its homolog MDMX (also known as MDM4) have been shown to exert oncogenic activity. These two proteins are best understood as negative regulators of the p53 tumor suppressor, although they may have additional p53-independent roles. Understanding the dysregulation of MDM2 and MDMX in human cancers and how they function either together or separately in tumorigenesis may improve methods of diagnosis and for assessing prognosis. Targeting the proteins themselves, or their regulators, may be a promising therapeutic approach to treating some forms of cancer. Twit Text FOAVip The Roles of MDM2 and MDMX in Cancer ????Annu Rev Pathol http://www.kidney.de/pget.php?&tw=1&pmid=27022975 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=27022975 #FOAvip English Wikipedia <ref>{{Cite pmid|27022975}}</ref> The Roles of MDM2 and MDMX in Cancer #MMPMID27022975 Karni-Schmidt O; Lokshin M; Prives C Annu Rev Pathol 2016[May]; 11 (ä): 617-44 PMID27022975show ga For more than 25 years, MDM2 and its homolog MDMX (also known as MDM4) have been shown to exert oncogenic activity. These two proteins are best understood as negative regulators of the p53 tumor suppressor, although they may have additional p53-independent roles. Understanding the dysregulation of MDM2 and MDMX in human cancers and how they function either together or separately in tumorigenesis may improve methods of diagnosis and for assessing prognosis. Targeting the proteins themselves, or their regulators, may be a promising therapeutic approach to treating some forms of cancer. äThe Roles of MDM2 and MDMX in Cancer (epmc).pdf DeepDyve Pubget Overpricing